Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eileen P, Dimond"'
Autor:
Bishow B, Adhikari, Scarlet, Shi, Eileen P, Dimond, Nonniekaye, Shelburne, Patrice, Desvigne-Nickens, Lori M, Minasian
Publikováno v:
Heart Fail Clin
Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held
Autor:
Bishow B. Adhikari, Scarlet Shi, Eileen P. Dimond, Nonniekaye Shelburne, Patrice Desvigne-Nickens, Lori M. Minasian
Publikováno v:
Heart Failure Clinics. 18:515-528
Autor:
Eileen P. Dimond, Bonnie Ky, Myrtle Davis, Eric J. Chow, W. Gregory Hundley, Pamela S. Douglas, Richard Fagerstrom, Carol J. Fabian, Joseph M. Unger, Karen M. Mustian, Justin D. Floyd, Saro H. Armenian, Lori M. Minasian, Bishow B. Adhikari, Steven E. Lipshultz
Publikováno v:
JACC CardioOncol
JACC. CardioOncology, Vol 1, Iss 1, Pp 105-113 (2019)
JACC. CardioOncology, Vol 1, Iss 1, Pp 105-113 (2019)
Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused solely on cancer treatment efficacy have not provided sufficient information on both CV risk factors and outco
Autor:
Joseph R. Carver, Anne O'Neill, Sheetal Mehta Kircher, Eileen P. Dimond, Bonnie Ky, Crystal S. Denlinger, Lynne I. Wagner, Joanna M. Brell, Jenica N. Upshaw
Publikováno v:
Clinical colorectal cancer. 18(1)
Introduction Fluoropyrimidines (FPDs) are a fundamental component of many chemotherapy regimens. Cardiotoxic adverse events (AEs) such as angina, ischemia, arrhythmias, and cardiomyopathy associated with 5-fluorouracil (5-FU) and capecitabine (CAPE)
Autor:
John C Leighton, Michael A Thompson, Keith S Lanier, Kathy Wilkinson, Thomas E Gribbin, Kimberly A. Csapo, Deborah L. Fleming, Angela Carrigan, Christie Ellison, Maria M Gonzalez, Eileen P Dimond, Jennifer C. Corpening, Ronald S. Go, Rebecca A Enos, Howard A. Zaren, Donna M Bryant, Andrea M. Denicoff, Suresh G. Nair Md, Jodi L Harr, Jinxiu Zhao
Publikováno v:
Journal of Oncology Practice. 9:e55-e61
The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) formed an Early-Phase Working Group to facilitate site participation in early-phase (EP) trials. The Working Group conducted a baseline assessment (BA) to describe the sites
Autor:
Eileen P. Dimond, Robin T. Zon, Bryan J. Weiner, Diane St. Germain, Andrea M. Denicoff, Kandie Dempsey, Angela C. Carrigan, Randall W. Teal, Marjorie J. Good, Worta McCaskill-Stevens, Stephen S. Grubbs
QUESTION ASKED: Is there a tool for sites engaged in cancer clinical research to use to assess their infrastructure and improve their research conduct toward exemplary levels of performance beyond the standard of Good Clinical Practice (GCP)? SUMMARY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0149a1c86513ec4294c2af8af4c565
https://europepmc.org/articles/PMC4976452/
https://europepmc.org/articles/PMC4976452/